rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
  name:
    name part: Grawunder, Ulf.
    role:
      role term: editor.
  name:
    name part: Barth, Stefan.
    role:
      role term: editor.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: gw
    date issued: 2017
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: XI, 181 p. 57 illus., 39 illus. in color. online resource.
  abstract: This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
  table of contents: Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P – Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.
  note: edited by Ulf Grawunder, Stefan Barth.
  subject:
    topic: Medicine
  subject:
    topic: Cancer research
  subject:
    topic: Antibodies
  subject:
    topic: Pharmacology
  subject:
    topic: Oncology
  subject:
    topic: Pharmacotherapy
  subject:
    topic: Biomedicine
  subject:
    topic: Pharmacology/Toxicology
  subject:
    topic: Antibodies
  subject:
    topic: Pharmacotherapy
  subject:
    topic: Cancer Research
  subject:
    topic: Oncology
  classification: RM1-950
  classification: 615
  related item:
    title info:
      title: Springer eBooks
  related item:
    title info:
      title: Milestones in Drug Therapy
  identifier: 9783319468778
  identifier: http://dx.doi.org/10.1007/978-3-319-46877-8
  record info:
    record creation date: 170407
    record change date: 20170407150027.0
    record identifier: 978-3-319-46877-8